SVS Medical LLC
Following two decades of revolutionary and groundbreaking developments in cosmetic and pharmaceutical packaging device development, including the globally acclaimed Single Vial System (SVS) technology, Prof. Dr. S Tsakas II, along with his father Prof. Dr. S Tsakas Sr., announces today some exciting news and updates from the scientific partnership that has been in operation since the early 1990s. Recently, the SVS technology has been endorsed, sponsored and funded by the Bill & Melinda Gates Foundation, World Health Organization, Prince's Trust, Scottish Enterprise and the Royal Society of Edinburgh for its ability to deliver twice as many medicines at half the cost worldwide.
SVS is exempt from clinical trials and unique registrations with the US FDA, European EMA and UK MHRA as well as exempt from CE certification through both the UK and EU. Moreover, it is merely a storage and reconstitution technology as opposed to a final product that will be used to deliver the actual medicines to the patient. As such, we are cleared for market launch immediately upon proving Stability and Non-Inferiority of the API within our technology.
Funded and endorsed by Bill & Melinda Gates Foundation, World Health Organization, Royal Society of Edinburgh, Prince’s Trust and Scottish Enterprise
Pilot Batches of Fully Functional SVS available by September 2016
Global Portfolio of Intellectual Property including Granted Patents & Trademarks
SVS offers the potential to deliver twice as many medicines at half the cost worldwide
Parenteral SVS is the pilot with ensuing Inhalation, Oral & Ocular SVS in the pipeline
Seeking Partner Pharmaceutical Companies to Pilot Test SVS with API of choice
- 117 Manning Street
Hudson, MA 01749
- [email protected]